Format

Send to

Choose Destination
Gut. 1998 Jun;42(6):845-9.

Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome.

Author information

1
Department of Psychosomatic Medicine, Tohoku University School of Medicine, Sendai, Japan.

Abstract

BACKGROUND:

Corticotropin-releasing hormone (CRH) plays a key role in modulating intestinal motility in stressed animals.

AIMS:

To evaluate the effect of CRH on intestinal motility in humans and to determine whether patients with irritable bowel syndrome (IBS) have an exaggerated response to CRH.

SUBJECTS:

Ten IBS patients diagnosed by Rome criteria and 10 healthy controls.

METHODS:

CRH (2 micrograms/kg) was intravenously administered during duodenal and colonic manometry and plasma adrenocorticotropic hormone (ACTH) was measured by radioimmunoassay.

RESULTS:

CRH induced motility of the descending colon in both groups (p < 0.001) and induced greater motility indexes in IBS patients than in controls (p < 0.05). CRH produced duodenal phase III motor activity in 80% of the subjects and duodenal dysmotility in 40% of IBS patients. Abdominal symptoms evoked by CRH in IBS patients lasted significantly longer than those in controls (p < 0.05). CRH induced significant increases in plasma ACTH levels in both groups (p < 0.001) and produced significantly higher plasma ACTH levels in IBS patients than in controls (p < 0.001).

CONCLUSION:

Human intestinal motility is probably modulated by exogenous CRH. The brain-gut in IBS patients may have an exaggerated response to CRH.

PMID:
9691924
PMCID:
PMC1727153
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center